Cytori Cell Therapy™ is for investigational use in the United States.
Cytori Cell Therapy™:
Cytori Therapeutics, Inc. develops cellular therapies designed to repair injured tissue, preserve function, improve quality of life, and modify disease progression. Known collectively as Cytori Cell Therapy™, these cellular therapeutics harness the unique attributes of living cells that are prepared from a patient’s own adipose tissue, known as Adipose-Derived Regenerative Cells (ADRCs).
Cytori develops nanomedicines using liposomal encapsulation technology designed to reduce toxicity while retaining the efficacy of both existing agents and novel compounds. For oncology patients, the size and composition of liposomal-encapsulated products are designed such that the chemotherapeutic agent can be delivered more selectively to the tumor1,2. Clinical trials have demonstrated that encapsulation can protect organs such as the heart from the toxic effects of the chemotherapy agents such as doxorubicin leading to a safety and efficacy profile that is superior to that of the non-encapsulated drug.2
Cytori exclusively uses human adipose tissue as the raw material to manufacture cellular therapies.
Why use adipose?
Human adipose tissue (fat tissue) is a unique reservoir of multiple types of cells that can contribute to the healing process. Cytori has developed technology to derive a heterogeneous cell population from adipose, also referred to as Adipose-Derived Regenerative Cells, or ADRCs. ADRCs can be used to create a number of cellular therapeutics. Since Cytori uses ADRCs from a patient’s own body, treatment with these cells avoid common transplantation issues such as cell rejection or disease transmission, and do not require anti-rejection or immunosuppression drugs.